You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
维亚生物(01873.HK)全年经调整利润升134.7%至3.18亿元 末期息1.5港仙
格隆汇 03-31 17:21

格隆汇3月31日丨维亚生物(01873.HK)公布,截至2019年12月31日止年度,集团实现收益3.23亿元人民币(单位下同),同比增长53.9%;毛利1.56亿元,同比增长47.8%;净利润2.66亿元,同比增长193.5%;经调整净利润3.18亿元,同比增长134.7%;基本每股盈利0.22港元,拟派末期股息每股0.015港元。

2019年全年,集团的CFS业务累计向客户交付超过1.37万个蛋白结构和独立药物靶标超过1200个。于报告期内,集团亦持续扩展广泛多元的优质客户群,客户订单增幅明显。CFS业务收入由去年同期1.55亿元大幅增加至2.46亿元,较去年同期增幅58.8%。2019年全年,集团EFS业务的收入为7750万元,较去年同期增长约40.0%。

报告期内,集团研发费用约为4500万元,较2018年度约2530万元增加77.9%。上述增加乃主要由于研发人员数量增加。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account